- Home
- CBRL vs KURA Comparison
CBRL vs KURA Comparison
Compare CBRL & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CBRL | KURA |
|---|---|---|
| Founded | 1969 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 645.7M | 765.8M |
| IPO Year | 1998 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CBRL | KURA |
|---|---|---|
| Price | $29.03 | $8.94 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $36.89 | $25.56 |
| AVG Volume (30 Days) | 1.0M | ★ 1.2M |
| Earning Date | 06-04-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.41% | N/A |
| EPS Growth | ★ 12.57 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,030,445,000.00 | $67,482,000.00 |
| Revenue This Year | N/A | $25.83 |
| Revenue Next Year | $3.62 | $103.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 3.56 | ★ 25.24 |
| 52 Week Low | $24.85 | $5.45 |
| 52 Week High | $68.09 | $12.49 |
Technical Indicators
Market Signals| Indicator | CBRL | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 52.20 | 55.08 |
| Support Level | $25.52 | $8.09 |
| Resistance Level | $29.87 | $9.60 |
| Average True Range (ATR) | 1.48 | 0.42 |
| MACD | 0.18 | 0.07 |
| Stochastic Oscillator | 72.56 | 77.41 |
Price Performance
Historical ComparisonAbout CBRL Cracker Barrel Old Country Store Inc
Cracker Barrel Old Country Store Inc operates hundreds of full-service restaurants throughout the United States. The Cracker Barrel stores consists of a restaurant with a gift shop. The restaurants serve breakfast, lunch and dinner. The gift shop offers a variety of decorative and functional items specializing in rocking chairs, holiday gifts, toys, apparel and foods.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.